ArticleClinical and translational radiation oncology2026
Survival outcomes of radiotherapy alone versus concurrent chemoradiotherapy in T1-2 head and neck cancer with low-volume disease: A multicenter cohort study.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal treatment strategy between definitive radiotherapy and concurrent chemoradiotherapy (CCRT) for patients with T1-2 head and neck cancer with low-volume nodal disease remains unclear due to limited supporting data. This study aimed to compare overall survival (OS) and progression-free survival (PFS) between the two treatment modalities. Methods: Patients with AJCC 7th edition stage T1-2N1-2a head and neck squamous cell carcinoma (HNSCC) were collected from multiple research centers, including the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC), the University Health Network (UHN), and Quebec, Canada. Inverse probability of treatment weighting (IPTW) was applied to balance baseline differences. Kaplan-Meier analysis and Cox proportional hazards models were used to compare OS and PFS between the two groups. Results: A total of 240 patients were included, with a median age of 57.8 years (IQR 52.0-65.1); 51 patients (21%) were HPV-negative. After IPTW adjustment, multivariable Cox analysis showed that CCRT did not provide a significant OS benefit compared with radiotherapy alone (hazard ratio [HR], 0.50; 95% CI, 0.20-1.24; Conclusions: This multicenter study demonstrated that while CCRT conferred limited OS benefit in patients with stage T1-2N1-2a HNSCC, it improved tumor progression control in a subset of patients. Careful evaluation of survival benefit versus treatment-related toxicity is warranted, and larger prospective studies are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.